Impact of portal vein embolization on expression of cancer stem cell markers in regenerated liver and colorectal liver metastases

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 12, 2010, Pages 1472-1479

  Williamson, James M L ^a   Thairu, Nagaru ^a   Katsoulas, Nicolas ^a   Stamp, Gordon ^b   Ahmad, Rabia ^b   Du Potet, Edmund ^a   Levicar, Natasha ^a   Gordon, Myrtle ^b   Stebbing, Justin ^b   Habib, Nagy A ^a   Jiao, Long R ^a  

^a Division of SORA   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer stem cell markers; Colorectal liver metastases; Portal vein embolization; Stem cell theory of carcinogenesis

Indexed keywords

CD133 ANTIGEN; CD44V ANTIGEN; CETUXIMAB; FLUOROPYRIMIDINE; FOLINIC ACID; IRINOTECAN; OCTAMER TRANSCRIPTION FACTOR 4; OXALIPLATIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; COLORECTAL CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; PORTAL VEIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VEIN EMBOLISM;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PORTAL VEIN;

EID: 78649254092     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.501523     Document Type: Article

References (27)

1. Tai MH, Chang CC, Kiupel M, et al. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005;26:495-502
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001;414:105-11
3. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Cancer 2003;3:895-901
4. Abate-Shen C. Homeobox genes and cancer: new OCTaves for and old tune. Cancer Cell 2003;4:329-30
5. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose dependent oncogenic fate determinant. Cancer Cell 2003;4:361-70
6. Monk M, Holding C. Human genes re-expressed in cancer cells. Oncogene 2001;20:8085-91
7. Resce M, Scholer HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 2001;19:271-8
8. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes Oct4, NANOG, STELLAR and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005;104:2255-65
9. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999;290:1779-82
10. Köbel M, Weichert W, Crüwell K, et al. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch 2004;445:456-64
11. Hart AH, Hartley L, Parker K, et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumours. Cancer 2005;104:2092-8
12. Al-Hajj M, Wicha MS, Benito-Hernadez A, et al. Prospective identification of tumourigenic breast cancer cells. PNAS 2003;100:3983-8
13. Wielenga V J M, Heider KH, Offerhaus GJ, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumour progression. Cancer Res 1993;53:4754-6
14. Cheng L. Establishing a germ cell origin for metastatic tumours using Oct4 immunohistochemistry. Cancer 2004;9:2006-10
15. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumourigenicity. Int J Cancer 2007;120:1444-50
16. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-15
17. Piechaczek C. CD133. J Biol Regul Homeost Agents 2001;15:101-2
18. Mackay CR, Terpe HJ, Stauder R, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82
19. Suo G, Han J, Wang X, et al. Oct4 pseudo genes are transcribed in cancer. Biochem Biophys Res Commun 2005;337:1047-51
20. Jackson PA, Green MA, Pouli A, et al. Relation between stage, grade, proliferation, and expression of p53 and CD44 in the adenomas and carcinomas of the colorectum. J Clin Pathol 1995;48:1098-101
21. Yamakado K, Takeda K, Matsumura K, et al. Regeneration of the un-embolised liver parenchyma following portal vein embolisation. J Hepatol 1997;27:871-80
22. Madoff DC, Hicks ME, Vauthey JN, et al. Transhepatic portal vein embolisation: anatomy, indications and technical considerations. Radiographics 2002;22:1063-76
23. Kokudo N, Tada K, Seki M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolisation. Hepatology 2001;34:267-72
24. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without portal vein embolisation. Arch Surg 2002;137:675-81
25. Wakabayashi H, Ishimura K, Okano K, et al. Is preoperative poral vein embolisation effective in improving prognosis after major hepatic resuscitation in patients with advanced-stage hepatocellular carcinoma? Cancer 2001;92:2384-90
26. Am Esch JS II, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow stem cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005;23:463-70
27. Fürst G, Schulteam Esch J, Poll LW, et al. Portal vein embolisation and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology 2007;243:171-9